The professor of neurology, psychiatry, and pharmacology at the NYU Grossman School of Medicine commented on the differences in mechanisms and clinical trial data between lecanemab and donanemab. [WATCH TIME: 5 minutes]
Martin Sadowski, MD, PhD
Advertisement
Articles by Martin Sadowski, MD, PhD
Advertisement
Latest Updated Articles
Differences Between Antiamyloid Therapies Lecanemab and Donanemab: Martin Sadowski, MD, PhDPublished: November 13th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission
2
FDA Approves Intrathecal Version of Zolgensma, Ozempic Falls Short in EVOKE Trials, Asundexian Meets End Point in Stroke Prevention Trial
3
NeurologyLive® Friday 5 — November 28, 2025
4
Exploring A Potential New Method to Evaluate CTE Progression in Living Patients
5
